Skip to content

EBIT at other companies

Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$110.03M-3.2%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$52.15M+1,073%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
-$9.36M-512%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$2.41M+614%
Theravance Biopharma logo
Theravance BiopharmaTBPH
-$9.48M+34.3%
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K
Free cash flow-$22.0M

Valuation

See full
Market cap$684.39M+102%
Enterprise value$728.29M+148%
P/E1.9×-7.2×
P/S2.3×+0.6×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Calculated from Rigel Pharmaceuticals’s reported figures.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rigel Pharmaceuticals's EBIT?
Rigel Pharmaceuticals (RIGL) reported EBIT of $11.89M in Q1 2026.
How has Rigel Pharmaceuticals's EBIT changed year-over-year?
Rigel Pharmaceuticals's EBIT decreased by 7.0% year-over-year, from $12.77M to $11.89M.
What is the long-term trend for Rigel Pharmaceuticals's EBIT?
Over 4 years (2021 to 2025), Rigel Pharmaceuticals's EBIT has grown at a 78.0% compound annual growth rate (CAGR), from -$12.5M to $125.47M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.